{"id":"d90662b3-8ab5-526e-a22f-984be68e0b78","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-ly-dipeptide-inhibits-ace","predicate":"inhibits","statement":"The Leu-Tyr dipeptide, liberated by fragmentation of subtilisin NAT, inhibited angiotensin-converting enzyme.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"f658bdaa-cd8c-5713-a572-017635e1dae9","mechanism_event_label":"The Leu-Tyr dipeptide, liberated by fragmentation of subtilisin NAT, inhibited angiotensin-converting enzyme.","subject":{"id":"ebb635e6-7f9d-5001-a165-266010ee41d1","slug":"peptide-leu-tyr","display_name":"Leu-Tyr dipeptide","entity_type_key":"peptide"},"object":{"id":"3d4b5a5c-1666-5b4a-b4e7-60bc6de0e626","slug":"ace","display_name":"Human angiotensin-converting enzyme / ACE","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"f658bdaa-cd8c-5713-a572-017635e1dae9","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-ly-dipeptide-inhibits-ace-event","event_type":"biochemical_relationship","label":"The Leu-Tyr dipeptide, liberated by fragmentation of subtilisin NAT, inhibited angiotensin-converting enzyme.","description":"ACE inhibition kinetics","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ebb635e6-7f9d-5001-a165-266010ee41d1","slug":"peptide-leu-tyr","display_name":"Leu-Tyr dipeptide","entity_type_key":"peptide"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3d4b5a5c-1666-5b4a-b4e7-60bc6de0e626","slug":"ace","display_name":"Human angiotensin-converting enzyme / ACE","entity_type_key":"protein"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"Not stated here","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Purified enzyme assay","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"LY dipeptide","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Its presence in the heat-inactivated material was confirmed by HPLC-MS. No human exposure measurement exists for it.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Purified enzyme assay","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The Leu-Tyr dipeptide, liberated by fragmentation of subtilisin NAT, inhibited angiotensin-converting enzyme.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. (2012) https://pubmed.ncbi.nlm.nih.gov/22453301/ DOI: 10.1039/c2fo10245e","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"ACE inhibition kinetics","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"221f7a2c-d17f-5a3f-93da-de30539dbb46","evidence_kind":"source_excerpt","locator":"Lines 697-697","start_line":697,"end_line":697,"excerpt":"The Leu-Tyr dipeptide, liberated by fragmentation of subtilisin NAT, inhibited angiotensin-converting enzyme.","model_system":"Purified enzyme assay","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}